MX365501B - Eliminacion de ligandos lixiviados de purificacion de afinidad. - Google Patents

Eliminacion de ligandos lixiviados de purificacion de afinidad.

Info

Publication number
MX365501B
MX365501B MX2015011994A MX2015011994A MX365501B MX 365501 B MX365501 B MX 365501B MX 2015011994 A MX2015011994 A MX 2015011994A MX 2015011994 A MX2015011994 A MX 2015011994A MX 365501 B MX365501 B MX 365501B
Authority
MX
Mexico
Prior art keywords
removal
leaked
affinity purification
purification ligand
contaminants
Prior art date
Application number
MX2015011994A
Other languages
English (en)
Other versions
MX2015011994A (es
Inventor
Ray Trejo Samuel
Perry Brake Robert
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50424772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX365501(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2015011994A publication Critical patent/MX2015011994A/es
Publication of MX365501B publication Critical patent/MX365501B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B01D15/1871—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a la eliminación de una porción grande de contaminantes de preparaciones de proteína manteniendo un alto nivel de recuperación mediante el uso de un medio de cromatografía de matriz de intercambio aniónico con tentáculos. Usando los métodos de la invención, los contaminantes lixiviados por cromatografía de afinidad pueden ser eliminados de preparaciones de proteínas recombinantes.
MX2015011994A 2013-03-14 2014-03-11 Eliminacion de ligandos lixiviados de purificacion de afinidad. MX365501B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361785038P 2013-03-14 2013-03-14
PCT/US2014/023682 WO2014159441A1 (en) 2013-03-14 2014-03-11 Removal of leaked affinity purification ligand

Publications (2)

Publication Number Publication Date
MX2015011994A MX2015011994A (es) 2015-12-01
MX365501B true MX365501B (es) 2019-06-05

Family

ID=50424772

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015011994A MX365501B (es) 2013-03-14 2014-03-11 Eliminacion de ligandos lixiviados de purificacion de afinidad.
MX2019006568A MX2019006568A (es) 2013-03-14 2015-09-09 Eliminacion de ligandos lixiviados de purificacion de afinidad.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019006568A MX2019006568A (es) 2013-03-14 2015-09-09 Eliminacion de ligandos lixiviados de purificacion de afinidad.

Country Status (18)

Country Link
US (3) US20160024144A1 (es)
EP (3) EP3395423B1 (es)
JP (1) JP6457479B2 (es)
AU (1) AU2014240596B2 (es)
CA (1) CA2904411A1 (es)
CY (1) CY1120353T1 (es)
DK (2) DK2969099T4 (es)
ES (2) ES2964601T3 (es)
FI (1) FI3395423T3 (es)
HK (1) HK1220159A1 (es)
HU (2) HUE038565T2 (es)
LT (2) LT2969099T (es)
MX (2) MX365501B (es)
PL (2) PL2969099T5 (es)
PT (2) PT2969099T (es)
SI (2) SI2969099T2 (es)
TR (1) TR201809050T4 (es)
WO (1) WO2014159441A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2969099T2 (sl) 2013-03-14 2022-04-29 Amgen Inc. Odstranjevanje izluženega afinitetnega purifikacijskega liganda
AR096713A1 (es) * 2013-06-25 2016-01-27 Cadila Healthcare Ltd Proceso de purificación para anticuerpos monoclonales
CN106536565A (zh) * 2014-06-13 2017-03-22 鲁宾有限公司 一种用于纯化TNFR‑Fc融合蛋白的方法
CN105214341B (zh) * 2015-09-17 2017-12-15 广州康盛生物科技有限公司 组合型吸附柱及其制备方法
US20200283472A1 (en) * 2016-03-29 2020-09-10 Navya Biologicals Pvt. Ltd A process for purification of fc-fusion proteins
JP7065105B2 (ja) * 2017-02-09 2022-05-11 ブラッコ・スイス・ソシエテ・アノニム 可溶性ｐｓｇｌ－１タンパク質変異体の精製のための方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
DE3811042A1 (de) 1988-03-31 1989-10-19 Merck Patent Gmbh Ionenaustauscher
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
ATE236249T1 (de) 1989-09-12 2003-04-15 Hoffmann La Roche Tfn-bindende proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
DE69332981T2 (de) 1992-10-23 2004-05-19 Immunex Corp., Seattle Methoden zur herstellung löslicher, oligomerer proteine
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
DE4333821A1 (de) 1993-10-04 1995-04-06 Merck Patent Gmbh Ionenaustauscher
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
DE19501726A1 (de) 1995-01-20 1996-07-25 Merck Patent Gmbh Polymerisationsfähige Derivate von Polyamiden
AU708239B2 (en) 1995-06-29 1999-07-29 Immunex Corporation Cytokine that induces apoptosis
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6149994A (en) 1996-06-21 2000-11-21 Merck Patent Gesellschaft Mit Beschrankter Haftung Polymerisable polyamide derivatives
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1998058253A1 (de) 1997-06-18 1998-12-23 Merck Patent Gmbh Verwendung monolithischer sorbentien für präparative chromatographische trennverfahren
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
WO2001036637A1 (en) 1999-11-17 2001-05-25 Immunex Corporation Receptor activator of nf-kappa b
FR2824568B1 (fr) * 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
CA2469815C (en) * 2001-12-21 2011-05-03 Immunex Corporation Methods for purifying protein
PL1869065T3 (pl) * 2005-03-11 2020-09-21 Wyeth Llc Sposób prowadzenia chromatografii podziałowej ze słabym wiązaniem
CA2668771C (en) * 2006-11-08 2016-03-15 Wyeth Rationally designed media for cell culture
CN102395597A (zh) * 2009-03-11 2012-03-28 惠氏有限责任公司 纯化小模块免疫药物蛋白的方法
JP5980782B2 (ja) * 2010-07-30 2016-08-31 ファイザー・インク タンパク質のタンデム精製
WO2012176158A1 (en) * 2011-06-24 2012-12-27 Dr. Reddy's Laboratories Limited Purification of chimeric protein
EP2729482B1 (en) * 2011-07-08 2018-03-07 Merck Sharp & Dohme Corp. Method for purifying fc-fusion protein
JP6326371B2 (ja) * 2011-11-04 2018-05-16 ザイムワークス，インコーポレイテッド Ｆｃドメインにおける変異を有する安定なヘテロ二量体抗体デザイン
SG10201701224UA (en) * 2012-03-12 2017-04-27 Merck Patent Gmbh Removal of protein aggregates from biopharmaceutical preparations in a flowthrough mode
SI2969099T2 (sl) 2013-03-14 2022-04-29 Amgen Inc. Odstranjevanje izluženega afinitetnega purifikacijskega liganda

Also Published As

Publication number Publication date
MX2015011994A (es) 2015-12-01
HK1220159A1 (zh) 2017-04-28
US20160024144A1 (en) 2016-01-28
EP3395423A1 (en) 2018-10-31
AU2014240596B2 (en) 2018-09-27
PL2969099T5 (pl) 2022-06-13
US11192919B2 (en) 2021-12-07
TR201809050T4 (tr) 2018-07-23
PT3395423T (pt) 2023-11-14
CA2904411A1 (en) 2014-10-02
US20190085021A1 (en) 2019-03-21
PT2969099T (pt) 2018-07-05
US11492372B2 (en) 2022-11-08
FI3395423T3 (fi) 2023-11-02
CY1120353T1 (el) 2019-07-10
ES2964601T3 (es) 2024-04-08
WO2014159441A1 (en) 2014-10-02
EP3395423B1 (en) 2023-09-20
SI2969099T1 (sl) 2018-09-28
EP2969099B2 (en) 2021-12-22
JP2016513643A (ja) 2016-05-16
PL2969099T3 (pl) 2018-10-31
HUE038565T2 (hu) 2018-10-29
US20220144886A1 (en) 2022-05-12
ES2674697T5 (es) 2022-04-19
EP2969099B1 (en) 2018-04-25
JP6457479B2 (ja) 2019-01-23
DK2969099T4 (da) 2022-03-14
DK2969099T3 (en) 2018-07-09
LT2969099T (lt) 2018-09-10
SI3395423T1 (sl) 2023-12-29
EP4026596A1 (en) 2022-07-13
PL3395423T3 (pl) 2024-03-18
LT3395423T (lt) 2023-12-11
MX2019006568A (es) 2019-08-22
SI2969099T2 (sl) 2022-04-29
AU2014240596A1 (en) 2015-09-24
EP2969099A1 (en) 2016-01-20
ES2674697T3 (es) 2018-07-03
DK3395423T3 (da) 2023-11-20
HUE064450T2 (hu) 2024-03-28

Similar Documents

Publication Publication Date Title
MX2019006568A (es) Eliminacion de ligandos lixiviados de purificacion de afinidad.
PH12017501115A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and method of use
PH12018501280A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
MX2016009672A (es) Cartuchos utiles en limpieza de soluciones de dialisis.
EP3360354A4 (en) SYSTEM AND METHOD FOR SELECTING A MEDIA CODING SCHEME
EP4324473A3 (en) Multiparametric nucleic acid optimization
MX2016002798A (es) Metodo para reutilizacion de cromatografia.
EP3186933A4 (en) Methods, systems, and computer readable media for virtual fabric routing
HK1257762A1 (zh) 純化梭菌神經毒素的方法
PL3312426T3 (pl) Koło tnące, tarcza tnąca oraz zespół tnący nadające się do pomp rozdrabniających
HK1251584A1 (zh) 在親和層析中減少宿主細胞蛋白的方法
WO2014058866A3 (en) Treatment of amyotrophic lateral sclerosis
EP3290432A4 (en) HIGH PERFORMANCE LIQUID CHROMATOGRAPHY METHOD FOR MIXTURES OF POLYPEPTIDES
MX2023008870A (es) Composiciones y metodos para reducir la carga biologica en cromatografia.
EP3278102A4 (en) Porous protein particles as carriers for actives
IN2015DN00922A (es)
SG10201803094QA (en) Monoliths with attached recognition compounds, arrays thereof and uses thereof
HK1251583A1 (zh) 在親和層析中減少宿主細胞蛋白的方法
MX2018003080A (es) Cartuchos utiles en soluciones de dialisis de limpieza.
MX2017006373A (es) Medios de cromatografía y restauración de desempeño de resina de intercambio iónico.
IL259180A (en) Improved protein separation in ion exchange chromatography
MY182103A (en) Adsorbent for hydrocarbon recovery
EP3169431A4 (en) High efficiency, ultra-stable, bonded hydrophilic interaction chromatography (hilic) matrix on superficially porous particles (spps)
AU2016902650A0 (en) An Automated Diamond Recovery System
AU2013904225A0 (en) An automated diamond recovery system

Legal Events

Date Code Title Description
FG Grant or registration